Genomic analyses identify molecular subtypes of pancreatic cancer
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63∆N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS G12D mutations are most commonly observed in pancreatic ductal adenocarcinoma (36%, [20]) and colorectal cancers (12%, [21]) and are also found in lung, endometrial and other cancers.”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [20]
In the citing paper
“Importantly, a study conducted genomic analyses on pancreatic cancer, involving 456 tumors primarily of PDAC and its variants. The research identified 32 significantly mutated genes grouped into 10 molecular mechanisms, including KRAS mutations in 92% of cases.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [87]
In the citing paper
“The majority of KRAS mutations are at codon 12, with the highest prevalence of G12D mutation (35%), followed by G12V (20–30%), G12R (10–20%), Q61 (~5%), G12C (1–2%), and other rare muations9–12.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [11]
In the citing paper
“Amongst these are four canonical mutations – KRAS (~85%), TP53 (60–70%), CDKN2A (>50%), and SMAD4 (~50%).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [51]
In the citing paper
“the genomic landscape of PDAC is also dominated by loss of function alterations of TP53, SMAD4 (also known as DPC4), and CDKN2A45,48–50.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [50]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Cited by
Items 501–600 of 1,020
Meier, A., Veeraraghavan, H., Nougaret, S., Lakhman, Y., Sosa, R. E., Soslow, R. A., Sutton, E. J., Hricak, H., Sala, E., & Vargas, H. A. (2018) · Abdominal Radiology · doi:10.1007/s00261-018-1840-5 · Cited by 76
Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?
Ben‐Aharon, I., Elkabets, M., Pelossof, R., Yu, K. H., Iacobuzio–Donahue, C. A., Leach, S. D., Lowery, M. A., Goodman, K. A., & O'Reilly, E. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3042 · Cited by 81
Self-citationJiang, J., Ye, S., Xu, Y., Chang, L., Hu, X., Ru, G., Guo, Y., Yi, X., Yang, L., & Huang, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01220 · Cited by 79
Antitumor Drugs and Their Targets
Dembić, Z. (2020) · Molecules · doi:10.3390/molecules25235776 · Cited by 81
“KRAS is the most frequently mutated oncogene in cancer, due to its presence in the predominant types like lung (NSCLC) [119,120], pancreatic [121] and colorectal [122] adenocarcinomas.”
BackgroundLeroux, C., & Konstantinidou, G. (2021) · Cancers · doi:10.3390/cancers13040799 · Cited by 88
Dhar, S. S., & Lee, M. G. (2021) · Oncotarget · doi:10.18632/oncotarget.27988 · Cited by 83
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 82
“Recently, Bailey and colleagues confirmed that K-RAS activation occurs in more than 90% of PDAC in a wide transcriptional analysis clustering 96 tumors with high epithelial content (20).”
BackgroundLuchini, C., Cros, J. F., Pea, A., Pilati, C., Veronese, N., Rusev, B. C., Capelli, P., Mafficini, A., Nottegar, A., Brosens, L. A. A., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.07.006 · Cited by 89
Self-citationDiagnosis of digestive system tumours
Washington, M. K., Goldberg, R. M., Chang, G. J., Limburg, P. J., Lam, A. K.-Y., Salto‐Tellez, M., Arends, M. J., Nagtegaal, I. D., Klimstra, D. S., Rugge, M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33210 · Cited by 87
Reese, M., & Dhayat, S. A. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01149-4 · Cited by 88
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 84
A Role for the WNT Co-Receptor LRP6 in Pathogenesis and Therapy of Epithelial Cancers
Raisch, J., Côté-Biron, A., & Rivard, N. (2019) · Cancers · doi:10.3390/cancers11081162 · Cited by 72
Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma
Venkat, S., Tisdale, A. A., Schwarz, J. R., Alahmari, A. A., Maurer, H. C., Olive, K. P., Eng, K. H., & Feigin, M. E. (2020) · Genome Research · doi:10.1101/gr.257550.119 · Cited by 84
Crawford, H. C., di Magliano, M. P., & Banerjee, S. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.042 · Cited by 77
Carbone, C., Piro, G., Agostini, A., Delfino, P., Sanctis, F. D., Nasca, V., Spallotta, F., Sette, C., Martini, M., Ugel, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002876 · Cited by 72
“…to tumor growth delay, IMO-2125 treatment failed to prolong mouse survival when injected with no immunogenic potential CDGs while showing significant effect when injected with the high immunogenic ones and, in a lesser extent, with the low immunogenic CDG, both alone and in combination with ICI.”
Self-citationLaw, H. C.-H., Lagundžin, D., Clement, E. J., Qiao, F., Wagner, Z. S., Krieger, K. L., Costanzo-Garvey, D. L., Caffrey, T. C., Grem, J. L., DiMaio, D. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1496 · Cited by 75
“Using transcriptional profiles of intact whole-tumor tissues, Bailey and colleagues classified four subtypes of PDAC (squamous, immunogenic, pancreatic progenitor, and ADEX), in which the squamous subtype is associated with significantly shorter survival than the other subtypes (10).”
BackgroundZhu, X., Cao, Y., Liu, W., Ju, X., Zhao, X., Jiang, L., Ye, Y., Jin, G., & Zhang, H. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00286-2 · Cited by 75
RetractedSWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
Botta, G. P., Kato, S., Patel, H., Fanta, P. T., Lee, S., Okamura, R., & Kurzrock, R. (2021) · JCI Insight · doi:10.1172/jci.insight.150453 · Cited by 78
“The International Cancer Genome Consortium (ICGC) dataset 24 found SWI/SNF alterations in 14% (46).”
MethodMechanisms of PDAC subtype heterogeneity and therapy response
Espinet, E., Klein, L., Puré, E., & Singh, S. K. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.08.005 · Cited by 93
Targeting KRAS: from metabolic regulation to cancer treatment
Shi, Y., Zheng, H., Wang, T., Zhou, S., Zhao, S., Li, M., & Cao, B. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02216-3 · Cited by 89
“These results resemble those of another comprehensive proteogenomic analysis of 140 pancreatic cancers from 7 countries, revealing a 97% KRAS mutation rate [201,202].”
miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma
Tesfaye, A. A., Azmi, A. S., & Philip, P. A. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.10.005 · Cited by 72
“The loss of tumor suppressor genes Ink4A (p16/CDKN2A), TP53, SMAD4, and BRCA2 has been well described in PDAC.(41) Ink4A acts as a checkpoint that controls the continued cellular proliferation fromKRAS activation and leads to cellular senescence.”
BackgroundZhou, Y., Chen, L., Zhang, Y., Hu, S., Dong, Z., Wu, M. J., Chen, Q., Zhuang, Z., & Du, X. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0113-2 · Cited by 78
“Some of them are considered as the tumor suppressor genes of PC, such as PLA2G1B, SERPINI2 and NR5A2 (Goonesekere et al., 2018; Bailey et al., 2016; Murtaugh, 2014).”
BackgroundDilemma and Challenge of Immunotherapy for Pancreatic Cancer
Wu, J., & Cai, J. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06183-9 · Cited by 74
“Screening for “immunogenic” subtypes that are more likely to benefit from immunotherapy is likely to achieve better results in patients with pancreatic cancer, as is the combination of immunotherapy with chemoradiotherapy [88].”
BackgroundSelf-citationSivapalan, L., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2020) · Pancreatology · doi:10.1016/j.pan.2020.12.017 · Cited by 79
Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C
Kettle, J. G., Bagal, S. K., Bickerton, S., Bodnarchuk, M. S., Boyd, S., Breed, J., Carbajo, R. J., Cassar, D. J., Chakraborty, A., Cosulich, S. C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00369 · Cited by 70
Chibaya, L., DeMarco, K. D., Lusi, C. F., Kane, G. I., Brassil, M. L., Parikh, C. N., Murphy, K. C., Chowdhury, S. R., Li, J., Ma, B., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj9366 · Cited by 77
Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases
Wooden, B., Goossens, N., Hoshida, Y., & Friedman, S. L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.065 · Cited by 69
Jäkel, C., Bergmann, F., Toth, R., Assenov, Y., van der Duin, D., Strobel, O., Hank, T., Klöppel, G., Dorrell, C., Grompe, M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01118-x · Cited by 69
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Young, K., Hughes, D. J., Cunningham, D., & Starling, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918816281 · Cited by 71
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
Casolino, R., Braconi, C., Malleo, G., Paiella, S., Bassi, C., Milella, M., Dreyer, S. B., Froeling, F. E. M., Chang, D. K.-F., Biankin, A. V., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.013 · Cited by 74
“Lastly, the immunogenic subtype, described by extending the analysis to the transcriptome of the immune infiltrate in the tumour microenvironment, was enriched for molecular signalling involved in immune cell infiltration and related immune response pathways.(54) Despite discrepancies in nomenclatures and methods of i…”
BackgroundInfluentialSelf-citationUnravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
Liu, Z., Parveen, N., Rehman, U., Aziz, A., Sheikh, A., Abourehab, M. A. S., Guo, W., Huang, J., Wang, Z., & Kesharwani, P. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01696-5 · Cited by 75
“Identification of the molecular subtypes of PC may enhance clinical results by enabling the design of customized therapies [65].”
BackgroundLarson, B. K., Tuli, R., Jamil, L. H., Lo, S. K., Deng, N., & Hendifar, A. E. (2018) · Pancreas · doi:10.1097/mpa.0000000000001117 · Cited by 68
Griffin, O. M., Duggan, S. N., Ryan, R. S., McDermott, R., Geoghegan, J., & Conlon, K. C. (2019) · Pancreatology · doi:10.1016/j.pan.2019.07.039 · Cited by 73
Mameishvili, E., Serafimidis, I., Iwaszkiewicz, S., Lesche, M., Reinhardt, S., Bölicke, N., Büttner, M., Stellas, D., Papadimitropoulou, A., Szabolcs, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901075116 · Cited by 74
Harnessing the Microbiome for Pancreatic Cancer Immunotherapy
Vitiello, G. A., Cohen, D. J., & Miller, G. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.10.005 · Cited by 68
BRCA-mutant pancreatic ductal adenocarcinoma
Lai, E., Ziranu, P., Spanu, D., Dubois, M., Pretta, A., Tolu, S., Camera, S., Liscia, N., Mariani, S., Persano, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01469-9 · Cited by 77
Nichol, J. N., Dupéré-Richer, D., Ezponda, T., Licht, J. D., & Miller, W. H. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.001 · Cited by 85
“Exome sequencing also revealed a significant frequency of UTX mutations in pancreatic tumors and gene expression profiling revealed that the mutations were enriched in a subtype in which p53 mutations were also enriched, and that subtype had a poorer prognosis (Bailey et al., 2016).”
BackgroundKenner, B. J., Chari, S. T., Maitra, A., Srivastava, S., Cleeter, D. F., Go, V. L. W., Rothschild, L. J., & Goldberg, A. E. (2016) · Pancreas · doi:10.1097/mpa.0000000000000701 · Cited by 67
Self-citationLiao, X., Huang, K., Huang, R., Liu, X., Han, C., Yu, L., Yu, T., Yang, C., Wang, X., & Peng, T. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s142557 · Cited by 67
“7,12,33 Due to the high mortality rate of pancreatic cancer, it is necessary to investigate reliable prognostic markers in order to select a subset of patients that would benefit from additional treatment options to improve survival.”
STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis
D’Amico, S., Shi, J., Martin, B. L., Crawford, H. C., Petrenko, O., & Reich, N. C. (2018) · Genes & Development · doi:10.1101/gad.311852.118 · Cited by 68
“S7C; Tan et al. 2014; Bailey et al. 2016).”
Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer
Dreyer, S. B., Pinese, M., Jamieson, N. B., Scarlett, C. J., Colvin, E. K., Pajic, M., Johns, A. L., Humphris, J. L., Wu, J., Cowley, M. J., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000003143 · Cited by 73
“enriched for transcriptional programs associated with proliferation, inflammation and metastasis.(20) Mechanistically, S100A2 hypomethylation and associated increased expression is a feature of the squamous subtype.”
BackgroundMethodResultInfluentialSelf-citationConstruction of a Plasmonic Chip for Metabolic Analysis in Cervical Cancer Screening and Evaluation
Shu, W., Wang, Y., Liu, C., Li, R., Pei, C., Lou, W., Lin, S., Di, W. J., & Wan, J. (2019) · Small Methods · doi:10.1002/smtd.201900469 · Cited by 67
Cdc6 as a novel target in cancer: Oncogenic potential, senescence and subcellular localisation
Lim, N., & Townsend, P. A. (2020) · International Journal of Cancer · doi:10.1002/ijc.32900 · Cited by 73
“pancreatic cancer, with major downstream repercussions in their signalling pathways.(3,4) Given the regulatory functions of”
BackgroundLi, H., Peng, C., Zhu, C., Nie, S., Qian, X., Shi, Z., Shi, M., Yan, L., Ding, X., Zhang, S., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01016-6 · Cited by 77
“[21], the three-group classification of Collisson et al.”
Mueller, A. C., Piper, M., Goodspeed, A. E., Bhuvane, S., Williams, J. S., Bhatia, S., Phan, A. V., Court, B. V., Zolman, K. L., Peña, B., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3892 · Cited by 68
“This is more significant in pancreatic cancer, where it has been shown that chronic inflammation is central to the disease’s natural history (55), with ECM activation further enhancing its aggressiveness (3, 7).”
BackgroundSplicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures
Jenkins, J. L., & Kielkopf, C. L. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.03.001 · Cited by 73
“Indeed, S34F mutations account for 60–80% of U2AF1 mutations in MDS [1, 3] and nearly all documented U2AF1 mutations in HCLv, lung adenocarcinomas and pancreatic cancers [13, 16].”
BackgroundBasso, D., Gnatta, E., Padoan, A., Fogar, P., Furlanello, S., Aita, A., Bozzato, D., Zambon, C., Arrigoni, G., Frasson, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20863 · Cited by 70
“Pancreatic ductal adenocarcinoma (PDAC) is still one of the most lethal forms of cancer worldwide despite the accumulating knowledge gained on its biology and genetics [1-3].”
BackgroundWatanabe, S., Shimada, S., Akiyama, Y., Ishikawa, Y., Ogura, T., Ogawa, K., Ono, H., Mitsunori, Y., Ban, D., Kudo, A., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32072 · Cited by 73
“Results Evaluation of clinicopathological significance of KDM6A in human PDAC Genomic analysis of PDAC has previously discovered a distinctive subtype with four features; poor patient prognosis, adenosquamous carcinoma, the QM subtype of the Collisson’s molecular classification and KDM6A attenuation.(3,4) We then perf…”
BackgroundMethodResultInfluentialWNT5B in Physiology and Disease
Suthon, S., Perkins, R. S., Bryja, V., Miranda‐Carboni, G. A., & Krum, S. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.667581 · Cited by 78
Beutel, A. K., Schütte, L., Scheible, J., Roger, E., Müller, M., Perkhofer, L., Kestler, A. M. T. U., Kraus, J. M., Kestler, H. A., Barth, T. F. E., et al. (2021) · Cancers · doi:10.3390/cancers13112539 · Cited by 65
“As such, GATA6 expression allows a distinction between classical and basal ‐ like subtypes [27]—with the latter being associated with chemoresistance and poor prognosis [28–30], while a high Ki ‐ 67 proliferation index is considered to have a negative impact on disease ‐ free survival [31–33].”
Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”
Hester, R., Mazur, P. K., & McAllister, F. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0900 · Cited by 74
“A study that analyzed publicly available data from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) revealed that while PDAC tumors lack the neoantigen diversity of melanomas, most tumors have mutations that result in candidate neoantigens, many of which would be expected to have ef…”
BackgroundMethodKing, R. J., Shukla, S. K., He, C., Vernucci, E., Thakur, R., Attri, K. S., Dasgupta, A., Chaika, N. V., Mulder, S. E., Abrego, J., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02132-6 · Cited by 75
“The donor information for the International Cancer Genome Consortium (ICGC) PDAC dataset collected by the Australian consortium was downloaded from the ICGC, while the normalized mRNA expression was downloaded from Supplemental Table 2 in a previous publication [59].”
MethodPersister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Zhou, X., An, J., Kurilov, R., Brors, B., Hu, K., Peccerella, T., Roessler, S. K., Pfütze, K., Schulz, A., Wolf, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00628-6 · Cited by 84
Self-citationMYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC
Fiorini, E., Malinova, A., Schreyer, D., Pasini, D., Bevere, M., Alessio, G., Rosa, D., D’Agosto, S. L., Azzolin, L., Milite, S., et al. (2025) · Nature · doi:10.1038/s41586-025-08721-9 · Cited by 82
Self-citationImproving outcomes of patients with pancreatic cancer
Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 81
“Conversely, the classic subtype is characterized by expression of gene networks involved in pancreatic endodermal differentiation and is thus associated with a favourable prognosis 104,112,114 .”
InfluentialSelf-citationMitochondrial mutations and metabolic adaptation in pancreatic cancer
Initiative, A. P. C. G., Hardie, R., van Dam, E., Cowley, M. J., Han, T.-L., Balaban, S., Pajic, M., Pinese, M., Iconomou, M., Shearer, R. F., et al. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0164-1 · Cited by 72
“As part of the APGI project, nuclear genome sequence data for the PDCL cohort was also available [4, 5, 31].”
Self-citationMolecular Events in the Natural History of Pancreatic Cancer
Oldfield, L. E., Connor, A. A., & Gallinger, S. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.005 · Cited by 73
Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance
Beatty, G. L., Eghbali, S., & Kim, R. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175232 · Cited by 64
Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer
Khomiak, A., Brunner, M., Kordes, M., Lindblad, S., Miksch, R. C., Öhlund, D., & Regel, I. (2020) · Cancers · doi:10.3390/cancers12113234 · Cited by 74
WNT Ligand Dependencies in Pancreatic Cancer
Aguilera, K. Y., & Dawson, D. W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.671022 · Cited by 72
The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
Sturm, N., Ettrich, T. J., & Perkhofer, L. (2022) · Cancers · doi:10.3390/cancers14010217 · Cited by 74
Evan, T., Wang, V. M.-Y., & Behrens, A. (2022) · Oncogene · doi:10.1038/s41388-022-02448-x · Cited by 79
“The role of the epigenome itself as a potential driver of PDAC has been highlighted by recent large-scale DNA sequencing studies, which have identified frequent mutations in epigenetic modifiers, including SWI/SNF components such as ARID1A and SMARCA4, the demethylase KDM6A, and acetyltransferase EP300 [43, 44].”
BackgroundNetwork-based approaches for modeling disease regulation and progression
Galindez, G., Sadegh, S., Baumbach, J., Kacprowski, T., & List, M. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.12.022 · Cited by 79
Oh, G., Wang, A., Wang, L., Li, J., Werba, G., Weissinger, D., Zhao, E., Dhara, S., Hernandez, R. E., Ackermann, A., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165934 · Cited by 71
Sans, M., Makino, Y., Min, J., Rajapakshe, K., Yip-Schneider, M., Schmidt, C. M., Hurd, M. W., Burks, J. K., Gomez, J. A., Thege, F. I., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1200 · Cited by 74
Self-citationSaving the spandrels? Adaptive genomic variation in conservation and fisheries management
Pearse, D. E. (2016) · Journal of Fish Biology · doi:10.1111/jfb.13168 · Cited by 64
ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signalling
Pinho, A. V., Van Bulck, M., Chantrill, L., Arshi, M., Sklyarova, T., Herrmann, D., Vennin, C., Gallego-Ortega, D., Mawson, A., Giry-Laterriere, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07497-z · Cited by 64
Self-citationOshi, M., Newman, S., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., Katz, M. H. G., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12102871 · Cited by 71
Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome
Juiz, N. A., Iovanna, J., & Dusetti, N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00246 · Cited by 72
“(49) proposed four subtypes: squamous, immunogenic, pancreatic progenitor, or aberrantly differentiated exocrine.”
BackgroundPandey, R., Zhou, M., Islam, S., Chen, B., Barker, N. K., Langlais, P. R., Srivastava, A., Luo, M., Cooke, L. S., Weterings, E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54545-9 · Cited by 69
Noel, P., Hussein, S., Ng, S., Antal, C. E., Lin, W., Rodela, E., Delgado, P., Naveed, S., Downes, M., Lin, Y. C., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-00285-9 · Cited by 70
WNT inhibition creates a BRCA‐like state in Wnt‐addicted cancer
Kaur, A., Sepramaniam, S., Lim, J. Y. S., Patnaik, S., Harmston, N., Lee, M. A., Petretto, E. G., Virshup, D. M., & Madan, B. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013349 · Cited by 68
“Additionally, a subset of pancreatic, mucinous ovarian, colorectal, gastric, adrenocortical and endometrial cancers harbor loss-of-function mutations in E3-ubiquitin ligases RNF43 or its paralog ZNRF3, or gene fusions leading to activation of Wnt agonists RSPO2/3 (Rspondin 2/3) (18-24).”
Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma
Chijimatsu, R., Kobayashi, S., Takeda, Y., Kitakaze, M., Tatekawa, S., Arao, Y., Nakayama, M., Tachibana, N., Saito, T., Ennishi, D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104659 · Cited by 71
“The tumor subtype is determined in each patient with PDAC (Bailey et al., 2016; Collisson et al., 2011; Moffitt et al., 2015; Network, 2017).”
BackgroundInterplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
Liu, Y.-H., Hu, C., Hsu, Y.-S., & Lee, W. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05259-w · Cited by 77
Hogenson, T. L., Xie, H., Phillips, W. J., Toruner, M. D., Li, J., Horn, I. P., Kennedy, D. J., Almada, L. L., Marks, D. L., Carr, R. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158060 · Cited by 75
Self-citationPergolini, I., Morales-Oyarvide, V., Mino-Kenudson, M., Honselmann, K. C., Rosenbaum, M. W., Nahar, S., Kem, M., Ferrone, C. R., Lillemoe, K. D., Bardeesy, N., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182855 · Cited by 63
Mirlekar, B., Michaud, D. E., Searcy, R., Greene, K., & Pylayeva‐Gupta, Y. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0710 · Cited by 70
Klett, H., Füllgraf, H., Levit‐Zerdoun, E., Hussung, S., Kowar, S., Küsters, S., Bronsert, P., Werner, M., Wittel, U. A., Fritsch, R., et al. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00108 · Cited by 65
“The ADEX subtype was exclusively associated to cluster 1 (exocrine/endocrine) with 26 genes being significantly up-regulated.”
BackgroundInfluentialBarnes, C. A., Chavez, M. I., Tsai, S., Aldakkak, M., George, B., Ritch, P. S., Dua, K. S., Clarke, C. N., Tolat, P. P., Hagen, C. E., et al. (2019) · Surgery · doi:10.1016/j.surg.2019.05.010 · Cited by 62
Wang, Z., Qin, J., Zhao, J., Li, J., Li, D., Popp, M. C., Popp, F., Alakus, H., Kong, B., Dong, Q., et al. (2020) · Theranostics · doi:10.7150/thno.43093 · Cited by 67
“The two major PDAC subtypes characterized to date are represented by the “classical” form and the “basal-like” form, each showing differing responses to chemotherapy drugs [10,11].”
BackgroundMethodInfluentialThomas, D., Sagar, S., Liu, X., Lee, H.-R., Grunkemeyer, J. A., Grandgenett, P. M., Caffrey, T. C., O’Connell, K. A., Swanson, B. J., Marcos-Silva, L., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.029 · Cited by 68
Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer
Zhang, X., Mao, T., Zhang, B., Xu, H., Cui, J., Jiao, F., Chen, D., Wang, Y., Hu, J., Xia, Q., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103897 · Cited by 66
From Machine Learning to Patient Outcomes: A Comprehensive Review of AI in Pancreatic Cancer
Tripathi, S., Tabari, A., Mansur, A., Dabbara, H., Bridge, C. P., & Daye, D. (2024) · Diagnostics · doi:10.3390/diagnostics14020174 · Cited by 76
“These models can help predict which patients are likely to benefit from specific therapies, allowing for more personalized treatment approaches and avoiding unnecessary interventions [39,40].”
BackgroundSivakumar, S., Jainarayanan, A., Arbe-Barnes, E. H., Sharma, P. K., Leathlobhair, M. N., Amin, S., Reiss, D. J., Heij, L. R., Hegde, S., Magen, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55424-2 · Cited by 76
“Multiple previous studies have shown that higher adaptive immune cell in fi ltration is associated with marginally better survival 8,18 , however, both adaptive and myeloid enriched PDAC patients have dismal prognoses 6 .”
Arnes, L., Liu, Z., Wang, J., Maurer, H. C., Sagalovskiy, I. R., Sánchez-Martín, M., Bommakanti, N. K., Garofalo, D. C., Balderes, D. A., Sussel, L., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314353 · Cited by 75
Macchini, M., Chiaravalli, M., Zanon, S. M., Peretti, U., Mazza, E. A., Gianni, L., & Reni, M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.013 · Cited by 66
Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype
Swayden, M., Iovanna, J., & Soubeyran, P. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e01055 · Cited by 67
Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets
Large, T. Y. S. L., Mantini, G., Meijer, L. L., Pham, T. V., Funel, N., van Grieken, N. C. T., Kok, B., Knol, J. C., van Laarhoven, H. W. M., Piersma, S. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138290 · Cited by 66
Liquid biopsies for management of pancreatic cancer
Samandari, M., Juliá, M. G., Rice, A. J., Chronopoulos, A., & Hernández, A. E. D. R. (2018) · Translational research · doi:10.1016/j.trsl.2018.07.008 · Cited by 69
Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight
Cortesi, M., Zanoni, M., Pirini, F., Tumedei, M. M., Ravaioli, S., Rapposelli, I. G., Frassineti, G. L., & Bravaccini, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010254 · Cited by 65
“Although the mechanisms leading to senescence bypass still remain to be clarified, the acquisition of loss-of-function mutations in tumor suppressor genes, such as TP53, CDKN2A, and SMAD4, leads to the establishment of a highly aggressive tumor [190].”
BackgroundFAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis
Chattaragada, M. S., Riganti, C., Sassoé‐Pognetto, M., Principe, M., Santamorena, M. M., Roux, C., Curcio, C., Evangelista, A., Allavena, P., Salvia, R., et al. (2017) · Oncogene · doi:10.1038/onc.2017.358 · Cited by 66
Self-citationCarrara, S., Leo, M. D., Grizzi, F., Correale, L., Rahal, D., Anderloni, A. A., Auriemma, F., Fugazza, A., Preatoni, P., Maselli, R., et al. (2018) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.12.031 · Cited by 61
The activating transcription factor 2: an influencer of cancer progression
Huebner, K., Procházka, J., Monteiro, A. C., Mahadevan, V., & Schneider‐Stock, R. (2019) · Mutagenesis · doi:10.1093/mutage/gez041 · Cited by 65
Zhuang, H., Zhou, Z., Ma, Z., Li, Z., Liu, C., Huang, S., Zhang, C., & Hou, B. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15990 · Cited by 74
Liquid biopsy in pancreatic cancer: the beginning of a new era
Yadav, D. K., Bai, X., Yadav, R. K., Singh, A., Li, G., Ma, T., Chen, W., & Liang, T. (2018) · Oncotarget · doi:10.18632/oncotarget.24809 · Cited by 68
“Aberrantly differentiated endocrine exocrine (KRAS, NR5A2, RBPJL, NEUROD1, and NKX2-2) [8].”
BackgroundZhang, S., Bao, Y., Shen, X., Pan, Y., Sun, Y., Xiao, M., Chen, K., Wei, H., Zuo, J., Saffen, D., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103067 · Cited by 61
“Somatic mutations of RBM10 frequently occur in several types of solid tumours, including LUAD, colorectal carcinomas [24], pancreatic ductal adenocarcinoma [25] and bladder cancer [26].”
BackgroundPreclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
Pham, T. D., Shields, M. A., Spaulding, C., Principe, D. R., Li, B., Underwood, P. W., Trevino, J. G., Bentrem, D. J., & Munshi, H. G. (2021) · Cancers · doi:10.3390/cancers13030440 · Cited by 67
“Similarly, immune cells, such as CD8+ T lymphocytes and CD68+ macrophages are pres rved during c lture (Figure 6), with most i mun logi‐ cal proteins staying stable and detectable during the cultu e process [18, 5,136].”
BackgroundPan‐cancer analyses reveal molecular and clinical characteristics of cuproptosis regulators
Wu, C., Tan, J., Wang, X., Qin, C., Long, W., Pan, Y., Li, Y., & Liu, Q. (2022) · iMeta · doi:10.1002/imt2.68 · Cited by 70
Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study
Duell, E. J., Luján‐Barroso, L., Sala, N., McElyea, S. D., Overvad, K., Tjønneland, A. M., Olsen, A., Weiderpass, E., Busund, L., Moi, L. L. H., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30790 · Cited by 63
“39 However, there is no evidence that each of these different molecular subtypes is associated with a unique miRNA profile.”
Precision medicine needs pioneering clinical bioinformaticians
Goméz-López, G., Dopazo, J., Cigudosa, J. C., Valencia, A., & Al‐Shahrour, F. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx144 · Cited by 72
Metadata
- Authors
- Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., Nourse, C., Murtaugh, L. C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M. J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P. J., Cloonan, N., Kassahn, K. S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L. N., Evers, L., Wu, J., Pinese, M., Cowley, M. J., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chantrill, L. A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Lovell, J. A., Merrett, N. D., Toon, C. W., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N. B., Graham, J. S., Duthie, F., Oien, K., Hair, J., Grützmann, R., Maitra, A., Iacobuzio-Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G. M., Initiative, A. P. C. G., Munzy, D. M., Fisher, W. E., Karim, S. A., Eshleman, J. R., Hruban, R. H., Pilarsky, C., Morton, J. P., Sansom, O. J., Scarpa, A., Musgrove, E. A., Bailey, U.-M. H., Hofmann, O., Sutherland, R. L., Wheeler, D. A., Gill, A. J., Gibbs, R. A., Pearson, J. V., Waddell, N., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- The University of Queensland (AU)
- Garvan Institute of Medical Research (AU)
- Baylor College of Medicine (US)
- University of Utah (US)
- South Australia Pathology (AU)
- Harvard University (US)
- University of Glasgow (GB)
- Camden and Campbelltown Hospitals (AU)
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Fiona Stanley Hospital (AU)
- Royal Adelaide Hospital (AU)
- Princess Alexandra Hospital (AU)
- The University of Western Australia (AU)
- Glasgow Royal Infirmary (GB)
- Beatson West of Scotland Cancer Centre (GB)
- NHS Greater Glasgow and Clyde (GB)
- Southern General Hospital (GB)
- Technische Universität Dresden (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- University of Verona (IT)
- Mayo Clinic (US)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Biankin, Andrew V.
- Grimmond, Sean M.
- ORCID
- Bailey, Peter
- Chang, David K.
- Johns, Amber L.
- Patch, Ann-Marie
- Gingras, Marie-Claude
- Christ, Angelika N.
- Quinn, Michael C.
- Murtaugh, L. Charles
- Harliwong, Ivon
- Manning, Suzanne
- Nourbakhsh, Ehsan
- Wani, Shivangi
- Holmes, Oliver
- Chin, Venessa
- Anderson, Matthew J.
- Kazakoff, Stephen
- Leonard, Conrad
- Newell, Felicity
- Wood, Scott
- Wilson, Peter J.
- Cloonan, Nicole
- Kassahn, Karin S.
- Quek, Kelly
- Robertson, Alan
- Pantano, Lorena
- Mincarelli, Laura
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark J.
- Jones, Marc D.
- Colvin, Emily K.
- Nagrial, Adnan M.
- Chantrill, Lorraine A.
- Mawson, Amanda
- Chou, Angela
- Pajic, Marina
- Scarlett, Christopher J.
- Pinho, Andreia V.
- Rooman, Ilse
- Samra, Jaswinder S.
- Kench, James G.
- Merrett, Neil D.
- Toon, Christopher W.
- Nguyen, Nam Q.
- Barbour, Andrew
- Zeps, Nikolajs
- Jamieson, Nigel B.
- Graham, Janet S.
- Oien, Karin
- Grützmann, Robert
- Maitra, Anirban
- Wolfgang, Christopher L.
- Lawlor, Rita T.
- Corbo, Vincenzo
- Bassi, Claudio
- Rusev, Borislav
- Salvia, Roberto
- Tortora, Giampaolo
- Petersen, Gloria M.
- Karim, Saadia A.
- Eshleman, James R.
- Hruban, Ralph H.
- Pilarsky, Christian
- Morton, Jennifer P.
- Sansom, Owen J.
- Scarpa, Aldo
- Bailey, Ulla-Maja Hagbo
- Hofmann, Oliver
- Wheeler, David A.
- Gill, Anthony J.
- Gibbs, Richard A.
- Pearson, John V.
- Waddell, Nicola
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2016-02-24
- Volume
- 531
- Issue
- 7592
- Pages
- 47-52
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2285093314
- Cited by
- 3,621
- References
- 52
- Citations by year
- 2026: 247 · 2025: 347 · 2024: 311 · 2023: 404 · 2022: 430 · 2021: 504 · 2020: 397 · 2019: 307 · 2018: 295 · 2017: 257 · 2016: 117
- FWCI
- 175.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (C29717/A17263, A12481, 17263, A18076, 12946, 20409, 11650, 21139, 22533)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Medical Research Council (MR/N005813/1)
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, molecular subtypes, recurrent mutations, KRAS, TP53, p63, KDM6A, DNA methylation, pancreatic progenitor cells, endocrine differentiation, immunosuppression, prognosis, transcriptional regulatory networks, histopathology
- MeSH terms
- Homeobox Protein Nkx-2.2, Animals, DNA-Binding Proteins, Humans, Mutation, Nuclear Proteins, Pancreatic Neoplasms, Prognosis, Transcription Factors, Transcription, Genetic, Trans-Activators, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Analysis, Tumor Suppressor Protein p53, Receptors, Cytoplasmic and Nuclear, Homeodomain Proteins, DNA Methylation, Carcinoma, Pancreatic Ductal, Genomics, Tumor Suppressor Proteins, Zebrafish Proteins, Cell Line, Tumor, Mice, Hepatocyte Nuclear Factor 3-beta, Hepatocyte Nuclear Factor 3-gamma, Basic Helix-Loop-Helix Proteins, Genes, Neoplasm, Gene Regulatory Networks, Histone Demethylases, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.